NONOF - Novo Nordisk CEO to testify before Senate on Ozempic pricing
2024-06-15 07:28:25 ET
More on Novo Nordisk
- Novo Nordisk: The Market Is Right, Don't Fight Against It
- Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study
- Novo Nordisk: Considerable Growth Beyond Ozempic
- Employee benefits survey finds marked increase in GLP-1 coverage
- Employer coverage for GLP-1s rising amid FDA label expansions: survey